How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Local radiation and phototherapy most cost-effective treatments for stage IA mycosis fungoides: a comparative decision-analysis model in the United States. (Abstract)

Local radiation and phototherapy most cost-effective treatments for stage IA mycosis fungoides: a comparative decision-analysis model in the United States. Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy

2018 Journal of American Academy of Dermatology

82. The Potential of Narrow Band UVB to Induce Sustained Durable Complete Remission off-Therapy in Stage I Mycosis Fungoides. (Abstract)

The Potential of Narrow Band UVB to Induce Sustained Durable Complete Remission off-Therapy in Stage I Mycosis Fungoides. Narrow Band UVB (NB UVB) is a first line therapy for stage I Mycosis Fungoides (MF) with complete response (CR) in 75%-85% of patients. However, long-term, off-therapy disease free survival (DFS) data are scarce.To assess the long-term DFS following NB UVB treatment stage I MF.An historic cohort of all stage I MF patients achieving CR with NB UVB and discontinuing any

2018 Journal of American Academy of Dermatology

83. Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides? Full Text available with Trip Pro

Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides? Follicular mucinosis (FM) can present as an acneiform eruption, and is usually a benign variant of primary FM unrelated to cutaneous T-cell lymphoma (CTCL). We report two cases of women in their twenties who presented with an acneiform rash on the face, arms and back. In both cases, pathological evaluation of the facial papules revealed predominantly mucinous degeneration of the follicular (...) epithelium, with insufficient lymphocytic infiltration or atypia to diagnose mycosis fungoides. These cases are similar to previous reports of acneiform FM. As none of the reported cases progressed to CTCL, we consider that overdiagnosis and overtreatment should be avoided in acneiform FM, but recommend long-term follow-up.© 2018 British Association of Dermatologists.

2018 Clinical & Experimental Dermatology

84. Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides. Full Text available with Trip Pro

Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides. Patients with mycosis fungoides (MF) developing tumors or extracutaneous lesions usually have a poor prognosis with no cure has so far been available. To identify potential novel biomarkers for MF at the tumor stage, a genomic mapping of 41 cutaneous lymphoma biopsies was used to explore for significant genes.The gene expression profiling datasets of MF were obtained from Gene Expression Omnibus database (GEO

2018 Medicine

85. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. Full Text available with Trip Pro

Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. To evaluate health care utilization, treatment patterns and costs among patients with mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL).This retrospective cohort study queried the HealthCore Integrated Research Database to identify patients ≥18 years with ≥2 diagnoses of MF-CTCL (ICD-9-CM code

2018 Journal of Dermatological Treatment

86. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Full Text available with Trip Pro

Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Mycosis fungoides (MF) is the most common type of cutaneous lymphoma. The term MF should be used only for the classical presentation of the disease characterized by the evolution of patches, plaques, and tumors or for variants showing a similar clinical course. MF is divided into 3 clinical phases: patch, plaque, and tumor stage, and the clinical course is usually protracted over years or decades

2018 Seminars in Cutaneous Medicine and Surgery

87. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. (Abstract)

Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, which typically presents with erythematous patches and plaques, histopathologically characterized by superficial infiltrates of small to mediumsized atypical epidermotropic T cells. Apart from this classic type of MF, many clinical and/or histopathologic variants have been described. Correct diagnosis of these MF variants

2018 Seminars in Cutaneous Medicine and Surgery

88. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Full Text available with Trip Pro

Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on manual Sézary counts but results from our EORTC survey confirm these are rarely performed in patch/plaque/tumour MF, and there is a trend towards using flow

2018 European Journal of Cancer

89. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. (Abstract)

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patients who had been diagnosed with mycosis fungoides/Sézary syndrome

2018 American Journal of Surgical Pathology

90. Unilesional mycosis fungoides is associated with increased expression of microRNA-17~92, and Th1 skewing. (Abstract)

Unilesional mycosis fungoides is associated with increased expression of microRNA-17~92, and Th1 skewing. The molecular basis of unilesional mycosis fungoides (MF), characterized by a solitary lesion that is clinicopathologically indistinguishable from multifocal patch or plaque MF (early MF), is unknown.To investigate the microRNA profile in unilesional MF distinguishing it from early MF.Biopsy samples of unilesional MF and early MF were evaluated with the Affymetrix microRNA array

2018 British Journal of Dermatology

91. SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

92. Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. Full Text available with Trip Pro

Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. •Active cancers and inflammation increase the risk for venous thromboembolism. It is unknown whether this applies to mycosis fungoides and parapsoriasis.•Patients with mycosis fungoides and parapsoriasis have increased risk for venous thromboembolism.•These findings should increase awareness of comorbidities as part of the disease spectrum in patients (...) with mycosis fungoides and parapsoriasis.Copyright © 2018. Published by Elsevier Inc.

2018 Journal of American Academy of Dermatology

93. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides. (Abstract)

CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides. CD8+ lymphomatoid papulosis is frequently indistinguishable histopathologically from primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma except for the expression of CD30. However, absent or weak expression of CD30 has been rarely reported in cases of CD8+ LyP.We aim to study the clinical and pathologic features of cases of CD8+ LyP (...) with CD30 expression and therefore resembled mycosis fungoides and type B LyP. CD5 and CD7 were frequently lost regardless of the CD30 status. Expression of cytotoxic markers was not different between the two groups. In the two cases with lack of CD30 expression, subsequent biopsies showed classic features of CD8+ LyP with strong expression of CD30.CD8+ LyP with lack of expression of CD30 may have distinct histopathologic features that resemble mycosis fungoides and LyP type B. Clinically

2018 International Journal of Dermatology

94. Tumoral Melanosis Arising on a Mycosis Fungoides Plaque Full Text available with Trip Pro

Tumoral Melanosis Arising on a Mycosis Fungoides Plaque 30203781 2019 01 30 2146-3131 35 6 2018 11 15 Balkan medical journal Balkan Med J Tumoral Melanosis Arising on a Mycosis Fungoides Plaque 447-448 10.4274/balkanmedj.2018.0936 Demirdağ Hatice Gamze HG 0000-0001-9484-2054 Department of Dermatology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey Akay Bengü Nisa BN 0000-0002-4896-1666 Department of Dermatology, Ankara

2018 Balkan medical journal

95. Early dermoscopic sign of folliculotropism in patients with mycosis fungoides Full Text available with Trip Pro

Early dermoscopic sign of folliculotropism in patients with mycosis fungoides 30479867 2018 12 07 2160-9381 8 4 2018 Oct Dermatology practical & conceptual Dermatol Pract Concept Early dermoscopic sign of folliculotropism in patients with mycosis fungoides. 328-329 10.5826/dpc.0804a17 Toncic Ruzica Jurakic RJ Department of Dermatology and Venereology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia. Drvar Daniela Ledic DL Department of Dermatology (...) , Croatia. Caccavale Stefano S Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Argenziano Giuseppe G Dermatology Unit, University of Campania, Nuovo Policlinico, Naples, Italy. eng Journal Article 2018 10 31 United States Dermatol Pract Concept 101585990 2160-9381 dermoscopy folliculotropic mycosis fungoides folliculotropism mycosis fungoides primary cutaneous lymphoma Competing interests: The authors have

2018 Dermatology practical & conceptual

96. Dosing of Brentuximab Vedotin for Mycosis Fungoides Patients

Dosing of Brentuximab Vedotin for Mycosis Fungoides Patients Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dosing (...) of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03587844 Recruitment Status : Recruiting First Posted : July 16, 2018 Last Update Posted : February 15, 2019

2018 Clinical Trials

97. Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03617224 Recruitment Status : Recruiting

2018 Clinical Trials

98. Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy Full Text available with Trip Pro

Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy Folliculotropic mycosis fungoides (FMF) is a variant of mycosis fungoides (MF) that is characterized clinically by variable types of skin eruptions, including plaques, acneiform lesions, and alopecic patches. Histopathologically, FMF is characterized by folliculotropic infiltrates.This study was conducted to scrutinize the clinical

2018 Annals of dermatology

99. Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Full Text available with Trip Pro

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use (...) for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

2018 Case reports in oncology

100. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data Full Text available with Trip Pro

Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data Nitrogen mustard is a chemotherapeutic agent that has a well-documented safety and efficacy profile in the treatment of cutaneous T-cell lymphoma. Development of nitrogen mustard formulations and treatment regimens has been studied extensively over the last 40 years. In the last 5 years, a new gel formulation has been developed

2018 Drug design, development and therapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>